OrganiGram Stock Forecast, Price & News

OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram or view top-rated stocks.

How has OrganiGram's stock been impacted by COVID-19 (Coronavirus)?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OGI stock has increased by 5.8% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19.

Are investors shorting OrganiGram?

OrganiGram saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 17,300,000 shares, an increase of 28.1% from the October 31st total of 13,510,000 shares. Based on an average trading volume of 6,830,000 shares, the short-interest ratio is presently 2.5 days.
View OrganiGram's Short Interest.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, January 11th 2022.
View our earnings forecast for OrganiGram.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) issued its earnings results on Monday, July, 12th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.02. The firm earned $16.55 million during the quarter, compared to the consensus estimate of $13.95 million. OrganiGram had a negative trailing twelve-month return on equity of 19.91% and a negative net margin of 190.24%.
View OrganiGram's earnings history.

What price target have analysts set for OGI?

8 brokers have issued twelve-month price targets for OrganiGram's shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate OrganiGram's share price to reach $4.04 in the next year. This suggests a possible upside of 121.7% from the stock's current price.
View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:

• Beena G. Goldenberg, Chief Executive Officer
• Derrick W. West, Chief Financial Officer
• Paolo de Luca, Chief Strategy Officer
• Borna Zlamalik, Vice President-Innovation
• Tim Emberg, Senior VP-Sales & Commercial Operations

Who are some of OrganiGram's key competitors?

Some companies that are related to OrganiGram include Prothena (PRTA), Lyell Immunopharma (LYEL), Harmony Biosciences (HRMY), Xencor (XNCR), Indivior (INVVY), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Nuvation Bio (NUVB), Trillium Therapeutics (TRIL), Agios Pharmaceuticals (AGIO), Global Blood Therapeutics (GBT), Cassava Sciences (SAVA), Ironwood Pharmaceuticals (IRWD), Atai Life Sciences (ATAI) and Avid Bioservices (CDMO).
View all of OGI's competitors.

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by many different retail and institutional investors. Top institutional investors include TD Asset Management Inc. (0.27%), Two Sigma Advisers LP (0.25%), Dimensional Fund Advisors LP (0.25%), Public Sector Pension Investment Board (0.21%), Penserra Capital Management LLC (0.21%) and Swiss National Bank (0.19%).

Which institutional investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Morgan Stanley, Millennium Management LLC, Deutsche Bank AG, Jump Financial LLC, Penserra Capital Management LLC, AdvisorShares Investments LLC, and UBS Group AG.

Which institutional investors are buying OrganiGram stock?

OGI stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Connor Clark & Lunn Investment Management Ltd., Two Sigma Advisers LP, Vontobel Holding Ltd., Goldman Sachs Group Inc., Swiss National Bank, HighTower Advisors LLC, and Public Sector Pension Investment Board.

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $1.82.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $545.71 million and generates $64.61 million in revenue each year. The company earns $-101.29 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 517 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

Where are OrganiGram's headquarters?

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at (844) 644-4726.